|
Online Database of Chemicals from Around the World | Search | Submit | Advertise |
Home >> Chemical Listing >> Sorafenib Related Compound 11>> Market Analysis Reports |
Market Analysis Reports of Sorafenib Related Compound 11 |
|
Onyx Pharmaceuticals Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... maximize commercialization opportunities for Nexavar (sorafenib) tablets, along with collaborator, Bayer ... ONX 0801 is a targeted oncology compound in Phase 1 clinical development that is designed ... for ONX 0801 and its related patents. Option Agreement with S* ... Global Small Molecule Multi-target Angiogenesis Inhibitor Market Growth 2024-2030 ... SMMTAI)represents a class of therapeutic compounds designed to inhibit angiogenesis by targeting ... and highlights key trends related to product segmentation, company ... and countries. Segmentation by Type: Sorafenib Sunitinib Apatinib Anlotinib Lenvatinib ... C-Raf Kinase Inhibitor– Pipeline Insight, 2020 ... Drugs Sorafenib/MG 010 - Metagone Biotech MG010 is a newly synthesized compound developed by ... together with another C-Raf inhibitor-Sorafenib. This MG-D-1609 causes mitochondria ... and acquisitions, licensing activities related to the C-Raf Kinase Inhibitor ... Global VEGFR-2 Inhibitor Market Growth 2024-2030 ... placed. A VEGFR-2 inhibitor is a pharmaceutical compound designed to selectively block the ... and highlights key trends related to product segmentation, company ... and countries. Segmentation by Type: Sorafenib Sunitinib Lenvatinib Vandetanib Cabozantinib ... Anti-VEGF Drugs Global Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application, Product Type ... retinal disorders like age-related macular degeneration (AMD) and ... and USD 25 billion, with a projected compound annual growth rate (CAGR) of 2.1% to 4.1 ... aflibercept), and small molecules (e.g., sunitinib, sorafenib), each designed to inhibit VEGF activity ... Apoptosis: Market Research Report This report analyzes the worldwide markets for Apoptosis in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Europe, Asia Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the ... Therapies for Resistant and Recurrent Metastatic Cancer The global cancer therapeutics market should reach $172.6 billion by 2022 from $121 billion in 2017 at a compound annual growth rate (CAGR) of 7.4%, from 2017 to 2022. The lung cancer market is expected to grow from $15.7 billion in 2017 to $22.6 billion ... Small Molecule Kinase Inhibitors: Market Research Report This report analyzes the Global Market for Small Molecule Kinase Inhibitors in Millions of US$ by the following Product Segments: Gleevec/Glivec, Tarceva, Sutent, Nexavar, Sprycel, Iressa, Tykerb/Tyverb, and Others. Annual forecasts are provided for the ... AXL kinase inhibitors - Pipeline Insights, 2022 ... Cabozantinib: Exelixis/Ipsen Exelixis’ flagship compound cabozantinib is a targeted agent that ... have been previously treated with sorafenib; for patients with advanced RCC ... Mergers and acquisitions, licensing activities related to the AXL kinase inhibitors ... Global Cancer Angiogenesis Inhibitors Market & Clinical Pipeline Insight Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location. Cancer is ever fastest growing global epidemic and one of the leading causes of death in the developed countries. It was observed that year 2015 ... Global Small Molecule Multi-target Angiogenesis Inhibitor Market Research Report 2025(Status and Outlook) ... SMMTAI)represents a class of therapeutic compounds designed to inhibit angiogenesis by targeting ... progression of diseases like age-related macular degeneration. This ... Tianqing Market Segmentation (by Type) Sorafenib Sunitinib Apatinib Anlotinib Lenvatinib ... |